Androgen deprivation therapy (ADT)

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Metastatic Hormone Sensitive Prostate Cancer

Drug Information

Target Indication

Metastatic Hormone Sensitive Prostate Cancer

Clinical Trial

Last updated: 2/9/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

ALPMY

Astellas Pharma

Related Pipeline

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer

Clostridium Difficile-associated Diarrhea (CDAD)

Psoriatic Arthritis

Anemia

Heart Transplantation